Prostate Specific Antigen News and Research RSS Feed - Prostate Specific Antigen News and Research

OncoTherapy Network discusses latest research on prostate cancer

OncoTherapy Network discusses latest research on prostate cancer

UBM Medica US announces that OncoTherapy Network, a leading online community to help oncologists and other clinicians gain a better understanding of the newest information available regarding the use of targeted therapies and immunotherapies, discusses some of the latest research on prostate cancer. [More]
Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. [More]
UAB offers MRI-US image fusion technique for prostate cancer detection

UAB offers MRI-US image fusion technique for prostate cancer detection

The latest advancement in prostate cancer detection is magnetic resonance imaging and ultrasound fusion-guided biopsy, which offers benefits for both patient and physician. [More]
Novel 'designer' nanodevice could improve cancer diagnostics, treatment

Novel 'designer' nanodevice could improve cancer diagnostics, treatment

Cancer diagnostics and treatment options could be drastically improved with the creation of a 'designer' nanodevice being developed by researchers from the UK, Italy, the US and Argentina. [More]
RNA molecules in tissue, urine samples can detect prostate cancer

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals. [More]
Researchers identify biomarker that can predict GS7 prostate cancer patients

Researchers identify biomarker that can predict GS7 prostate cancer patients

Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Early detection of cancers on the horizon with supersensitive nanodevice

Early detection of cancers on the horizon with supersensitive nanodevice

Extremely early detection of cancers and other diseases is on the horizon with a supersensitive nanodevice being developed at The University of Alabama in Huntsville in collaboration with The Joint School of Nanoscience and Nanoengineering in Greensboro, NC. [More]
Storage symptoms more severe in men with comorbid diabetes

Storage symptoms more severe in men with comorbid diabetes

A study of men with lower urinary tract symptoms and benign prostatic hyperplasia suggests that the presence of comorbid diabetes is associated with more severe urological symptoms. [More]
Guidelines recommending routine prostate cancer screening for elderly men have minimal effect

Guidelines recommending routine prostate cancer screening for elderly men have minimal effect

The effect of guidelines recommending that elderly men should not be routinely screened for prostate cancer "has been minimal at best," according to a new study led by researchers at Henry Ford Hospital. [More]
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. [More]
American men have worse access to reproductive and sexual health care, shows research

American men have worse access to reproductive and sexual health care, shows research

Compared with women, American men have worse access to reproductive and sexual health care, research shows, a disparity fueled in part by the lack of standard clinical guidelines on the types and timing of exams, tests and treatments that should be offered to all men of reproductive age. [More]
Metabolic syndrome has inverse link with LUTS in Korean men

Metabolic syndrome has inverse link with LUTS in Korean men

The metabolic syndrome may be protective against lower urinary-tract symptoms, a study of Korean middle-aged men has found. [More]
Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International plc announced today that it has introduced the first and only generic 2% topical testosterone gel, an authorized generic of FORTESTA® Gel (testosterone gel) CIII. [More]
Widespread awareness, better treatment lower prostate cancer death rates

Widespread awareness, better treatment lower prostate cancer death rates

Fewer men are being diagnosed with and dying from prostate cancer these days. While that is due in part to widespread awareness and better treatment, it is also the result of more judicious screening. [More]
Pathologists help determine prostate cancer patient’s eligibility for active surveillance

Pathologists help determine prostate cancer patient’s eligibility for active surveillance

Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. [More]
Viewpoints: Threat to drug development; GOP's Obamacare criticism tempered; finding doctors for seniors

Viewpoints: Threat to drug development; GOP's Obamacare criticism tempered; finding doctors for seniors

An invasive species has been introduced into the U.S. health innovation ecosystem, with a growing danger of permanent damage to the development of specialty drugs. [More]
BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

BRCA2 mutations herald poor prognosis in screen-detected prostate cancer

Among men with prostate cancer detected on screening, survival among those with a mutation in the BRCA2 gene is much poorer than in those without such a mutation, researchers report. [More]
MRI technology improves prostate cancer diagnosis

MRI technology improves prostate cancer diagnosis

Oncologists at UC San Diego Moores Cancer Center are the first in San Diego to meld magnetic resonance imaging (MRI) technology with a traditional ultrasound prostate exam to create a three-dimensional map of the prostate that allows physicians to view growths that were previously undetectable. [More]
Prostate cancer screening could cut deaths by one fifth

Prostate cancer screening could cut deaths by one fifth

Routine screening for prostate cancer could reduce the number of people who die from the illness by around a fifth, according to findings from a major European trial. [More]